-1.19%
14.33%
-10.25%
-4.39%
45.53%
-31.91%
0.60%
AI Spotlight on DNLI
Company Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.
It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J.Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG.to develop antisense therapies in the field of neurodegenerative diseases.
The company was formerly known as SPR Pharma Inc.and changed its name to Denali Therapeutics Inc.in March 2015.
Denali Therapeutics Inc.was incorporated in 2013 and is headquartered in South San Francisco, California.
Market Data
| Last Price | 23.3 |
| Change Percentage | -1.19% |
| Open | 23.37 |
| Previous Close | 23.58 |
| Market Cap ( Millions) | 3353 |
| Volume | 1042169 |
| Year High | 33.33 |
| Year Low | 14.56 |
| M A 50 | 22.8 |
| M A 200 | 23.25 |
Financial Ratios
| FCF Yield | -11.20% |
| Dividend Yield | 0.00% |
| ROE | -32.93% |
| Debt / Equity | 3.98% |
| Net Debt / EBIDTA | 7.68% |
| Price To Book | 2.99 |
| Price Earnings Ratio | -9.24 |
| Price To FCF | -8.93 |
| Price To sales | -10.99 |
| EV / EBITDA | -6.68 |
News
- Jan -21 - Denali Gains 26.6% in a Year: How Should You Play the Stock?
- Jan -15 - Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
- Jan -09 - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Jan -09 - DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
- Jan -07 - Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
- Jan -06 - Denali Therapeutics ALS drug fails in mid-stage trial
- Jan -06 - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
- Jan -03 - Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
- Dec -06 - Denali Starts Dosing in Phase II Parkinson's Disease Study
- Nov -16 - Denali Has A Neurodegenerative Edge Despite Market Skepticism
- Nov -08 - Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
- Nov -06 - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- Oct -29 - Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Sep -16 - Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
- Sep -04 - Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
- Sep -03 - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
- Aug -20 - Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
- Aug -14 - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
- Aug -06 - Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
- Aug -01 - Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutics
Expected Growth : 10.43 %
What the company do ?
Denali Therapeutics Inc. focuses on developing therapies for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS, using its proprietary enzyme transport technology.
Why we expect these perspectives ?
Denali Therapeutics' 10.43% growth is driven by its innovative pipeline of neurodegenerative disease treatments, strong partnerships with Biogen and Sanofi, and increasing R&D investments. The company's focus on blood-brain barrier penetration technology and its potential to address unmet medical needs in Alzheimer's and Parkinson's diseases also contribute to its growth momentum.
Denali Therapeutics Inc. Products
| Product Range | What is it ? |
|---|---|
| DNL151 | A small molecule inhibitor of RIPK1, a key regulator of necroptosis and inflammation, for the treatment of ALS and other neurodegenerative diseases. |
| DNL201 | A small molecule inhibitor of LRRK2, a key regulator of lysosomal function, for the treatment of Parkinson's disease. |
| DNL788 | A small molecule inhibitor of ATG4, a key regulator of autophagy, for the treatment of neurodegenerative diseases. |
| DNL593 | A small molecule inhibitor of DJ-1, a key regulator of mitochondrial function, for the treatment of Parkinson's disease. |
| DNL519 | A small molecule inhibitor of tau, a key regulator of neurodegeneration, for the treatment of Alzheimer's disease and other tauopathies. |
Denali Therapeutics Inc.'s Porter Forces
Threat Of Substitutes
Denali Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for neurodegenerative diseases.
Bargaining Power Of Customers
Denali Therapeutics Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective treatments.
Bargaining Power Of Suppliers
Denali Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.
Threat Of New Entrants
Denali Therapeutics Inc. has a high threat of new entrants due to the growing interest in biotechnology and the potential for new companies to enter the market.
Intensity Of Rivalry
Denali Therapeutics Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.82% |
| Debt Cost | 3.95% |
| Equity Weight | 95.18% |
| Equity Cost | 10.89% |
| WACC | 10.56% |
| Leverage | 5.07% |
Denali Therapeutics Inc. : Quality Control
Denali Therapeutics Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CLDX | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
| RVMD | Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
Denali Therapeutics
A-Score
1-Year Total Return ->
🥉
Revolution Medicines
A-Score
1-Year Total Return ->
4
Amicus Therapeutics
A-Score
1-Year Total Return ->
5
Celldex Therapeutics
A-Score
1-Year Total Return ->
6
